Tozorakimab (MEDI3506): an anti-IL-33 antibody that inhibits IL …
WEBJun 17, 2023 · Tozorakimab is a novel therapeutic agent with a dual mechanism of action that blocks IL-33red and IL-33ox signalling, offering potential to reduce inflammation and epithelial dysfunction in human...
Pipeline - AstraZeneca
WEBAstraZeneca’s deep pipeline of medicines focusing on their key therapeutic areas.
Efficacy and Safety of Tozorakimab in Patients Hospitalised for …
WEBThe purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.
A randomised phase 2a study to investigate the effects of blocking ...
WEBOct 2, 2023 · Tozorakimab is a high-affinity human IgG1 monoclonal antibody that neutralises IL-33 and has therapeutic potential to improve clinical outcomes in patients hospitalised with COVID-19.
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody
WEBTozorakimab significantly reduced serum IL-5 and IL-13 levels in patients with COPD compared with placebo. Overall, tozorakimab was well tolerated, with a linear, time-independent serum PK profile. Additionally, biomarker studies demonstrated proof of …
Long-term Efficacy and Safety of Tozorakimab in Participants with ...
WEBA Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO).
Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33
WEBMar 1, 2023 · Tozorakimab is a novel therapeutic agent with a dual mechanism of action that blocks IL-33red and IL-33ox signalling, offering potential to reduce inflammation and epithelial dysfunction in human disease.
AstraZeneca IL-33 drug fails to improve COPD breathing in ph. 2
WEBSep 8, 2024 · AstraZeneca is running a trio of phase 3 trials for tozorakimab in patients with a history of COPD exacerbations, with data set to read out “after 2025,” Brindicci said.
A randomised phase 2a study to investigate the effects of blocking ...
WEBOct 2, 2023 · We examined the efficacy and safety of tozorakimab, a monoclonal antibody that neutralises IL-33, in improving outcomes in ACCORD-2 (EudraCT: 2020-001736-95). Methods: ACCORD-2 was an open-label, phase 2a …
Targeting interleukin-33 and thymic stromal lymphopoietin …
WEBMar 3, 2023 · AstraZeneca's anti-IL-33 antibody, tozorakimab (MEDI3506), currently has phase 2a and phase 3 studies underway in COPD. Clinical data suggest that anti-IL-33/ST2 therapies could benefit patients with both T2 and non-T2 asthma, the latter being an area where there remains high unmet need, as well as …
Skip to content